QureTech Bio™

New antibiotic class showing no resistance development

Why innovation is needed to fight antimicrobial resistance (AMR)

INFECTIONS CAUSES MILLIONS OF DEATH

1.27 M deaths per year due to drug resistant bacterial infections
(The Lancet, 2022)

Ranked among the top ten threats to global health according to WHO

URGENT NEED FOR NEW TREATMENTS

The current pipeline is insufficient to meet the treat of AMR

Only 27 new antibiotics in clinical development against priority pathogens

RESISTANCE THREATENS THE WHOLE HEALTHCARE SYSTEM

Company

Vision
Develop a new class of antibiotics to combat infectious diseases and the occurrence of antibiotic resistance

Business Model:
Develop drugs solitary or in partnerships with other biotech companies, before licensing to pharmaceutical industry

Strenght:
Strong scientific team with highly reputed scientists from Umeå University (SWE) and Washington University (USA)
Lead investor onboard
Large business network within Sweden and USA

FOUNDERS

Fredrik Almqvist

Research Director,
Professor in Organic Chemistry at Umeå University, Sweden

Scott Hultgren

CSO,
Professor in Molecular Microbiology at Washington University, St. Louis

Sven Bergström

Chairman,
Professor in Microbiology at Umeå University, Sweden

Jörgen Johansson

Board member,
Professor in Molecular Microbiology at Umeå University, Sweden

Christina Stallings

Vice Chairman,
Professor in Molecular Microbiology at Washington University, St. Louis

GmPcides: new antibiotic class with anti-resistance properties

Key advantages of GmPcides include:

- Novel family of small molecules with new mode of action (detailed studies ongoing)
- Excellent microbiological profile
- Bactericidal effect on antibiotic-resistant Gram-positive bacteria
- Low likelihood of resistance development
- No signs of pre-existing resistance, MIC_{90} in recent clinical isolates of *S. aureus* 2-4 µg/mL
- Robust and reliable chemical platform that allows fine tuning of properties important for drug development
- Strong patent protection

	Candidate drug	New class	New MoA	Indication/target	Discovery	Hit to Lead	Lead to candidate	Candidate selection	Support/Partner
HEALTHCARE ASSOCIATED INFECTIONS	GmPcides	✓	✓	*Acute bacterial skin and skin structure infections*					ENABLE-2 Antibacterial Drug Development Engine; VINNOVA

Nye, et al 2022: https://doi.org/10.1073/pnas.2210912119

Target Product Profile

- **Product:** first-in-class antibiotic to be used for monotherapy treatment of serious infections caused by Gram-positive pathogens
- **Initial target patient population:** Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- **Patient population:** Patients with bacterial infections caused by *Staphylococcus aureus* (including MRSA), *Streptococcus pyogenes,* other *Streptococcus* species and *Enterococcus faecalis (*including VRE).
- **Route of administration:** intravenous (optimally iv and oral)
- **Unmet need:** the unmet need for ABSSSI is predominantly driven by a demand for effective anti-MRSA treatment options
- **Competitive differentiation:** novel class, activity against multi drug-resistant bacteria, low propensity to cause resistance, novel mode of action (tbc), bactericidal activity in MRSA biofilm

Opportunity

- Attention is raising on the urgent need for new antibiotics – from healthcare, through politicians to pharma industry
  - International initiatives for reimbursements of antibiotics are coming
  - Pharma industry place large assets in common funds to develop new antibiotics

- QureTech Bio are well positioned with antibiotics showing low levels of resistance
  - QureTech compounds, GmPcides, are built on a solid and flexible chemical platform
  - QureTech have world leading scientist in their team

- QureTech Bio is moving towards pre-clinical phase and are seaching for long term investors for the upcoming fund raising later this year

QureTech Bio™



Contact us:

Helén Fält
CEO
Email: helen.falt@quretech.com

Fredrik Almqvist
Research Director
Email: fredrik.almqvist@quretech.com

www.quretech.com